TY - JOUR T1 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation JO - Health Technology Assessment UR - http://eprints.whiterose.ac.uk/99486/ PY - 2016/04/01 AU - Stevenson M AU - Archer R AU - Tosh J AU - Simpson E AU - Everson-Hock E AU - Stevens J AU - Hernandez-Alava M AU - Paisley S AU - Dickinson K AU - Scott D AU - Young A et al ED - DO - DOI: 10.3310/hta20350 VL - 20 IS - 35 SP - 1 EP - 610 Y2 - 2025/04/15 ER -